Sanara MedTech Inc.
Sanara MedTech Inc. is a U.S.-based medical technology company focused on products and services for surgical care, chronic wound care, and skincare. Its business is organized around Sanara Surgical and THP, combining surgical-site products, bone fusion products, and value-based wound care services across the care continuum in the United States.
Tilikausi 2025 · muutos edellisvuodesta
Kehitys 2020–2025
Liiketoiminta
Osuus liikevaihdostaCollagen-based and surgical-site products used to support wound healing and irrigation in sterile settings.
Biologic and matrix products used in orthopedic and surgical bone grafting and fusion procedures.
THP-related wound care and skincare services and programs delivered through provider partnerships.
Internal development work and product pipeline activities led by Rochal Technologies.
Tuotteet
Raportoitu · osuus liikevaihdosta- Soft Tissue Repair Products88,6 %
- Bone Fusion Products11,4 %
Lähde: 10-K FY2025, yhtiön tuotelinjoittain raportoima liikevaihto (SEC XBRL). Osuudet on laskettu näytetyistä riveistä ja ne summautuvat 100 %:iin.
Asiakkaat
The company sells primarily to hospitals and other acute care facilities that use its products in surgical and sterile care settings. It also serves wound care providers and other healthcare organizations that participate in value-based wound and skincare programs. Demand is driven by clinical adoption, procedure volumes, and the ability of products and services to fit into hospital and provider workflows.
Buy soft tissue repair and bone fusion products for use in operating rooms and sterile environments.
Adopt THP value-based wound care and skincare services to support patient management across care settings.
Influence product selection for surgical-site management, irrigation, and bone grafting applications.
Evaluate products and services based on clinical outcomes, workflow fit, and total cost of care.
Strategia
The company is building a broader platform across surgical products, wound care, and skincare services, with THP positioned as a key growth initiative. It is also expanding distribution, developing new products through Rochal Technologies, and pursuing acquisitions and partnerships to support a value-based care model.
This creates a services layer alongside products and broadens the company’s care continuum offering.
Higher adoption of core products supports scale in hospitals and acute care facilities.
New products and technologies can extend the portfolio and support future growth.
External growth can add capabilities, provider access, and service offerings.
Maantiede
Sanara MedTech operates primarily in the United States, where it sells through an expanding independent distribution network and direct clinical relationships. Its reported growth has been tied to increased market penetration and geographic expansion within new and existing U.S. markets. The company does not disclose a meaningful non-U.S. revenue mix in the provided materials.
Riskit
The business depends on clinical acceptance, reimbursement dynamics, and the ability to commercialize licensed and internally developed products. It also faces execution risk in acquisitions, debt compliance, and the buildout of THP, while product quality, intellectual property, and supply chain disruptions can affect adoption and continuity.
Revenue depends on surgeons, hospitals, and providers adopting the products in routine care.
Healthcare purchasing and service economics are influenced by labeling, marketing, and reimbursement rules.
Kohdistuu: Wound care and skincare services
The company uses credit facilities and equity financing to fund growth and acquisitions.
Kohdistuu: CRG Term Loan and future capital needs
The THP strategy relies on acquisitions and partner relationships that may not deliver expected benefits.
Kohdistuu: CarePICS and future acquisitions
Manufacturing, licensing, and distribution disruptions can interrupt sales and margins.
Kohdistuu: Licensed products and external manufacturers
Defects or IP disputes can limit commercialization and damage customer trust.
Kohdistuu: Surgical and bone fusion portfolio
Kirjanpito
Harkinnanvaraiset erätRevenue is recognized when the customer receives the product, so shipment and delivery timing affect quarterly comparability.
Vaikutus: Quarterly revenue and gross profit
The company records acquired assets at fair value and remeasures contingent consideration over time.
Vaikutus: Goodwill, intangibles, and noncash fair value gains/losses
Product licenses, patents, customer relationships, and assembled workforces are amortized over finite lives.
Vaikutus: Operating expenses and earnings
The company reports related-party receivables, payables, and advisory arrangements that require disclosure and monitoring.
Vaikutus: Balance sheet and governance transparency
Management must estimate fair values for acquired assets and liabilities, which can change reported results.
Vaikutus: Acquisition accounting and future impairment risk
Samankaltaisia listattuja yhtiöitä
Julkisesti listattuja yhtiöitä, joilla on samankaltainen liiketoiminta.
Celularity Inc
CELU · Pharmaceutical Preparations
Bicara Therapeutics Inc.
BCAX · Pharmaceutical Preparations
LENSAR, Inc.
LNSR · Surgical & Medical Instruments & Apparatus
Solana Co
HSDT · Finance Services
Solana Co is a U.S.-based public company organized around a Solana digital asset treasury strategy, with Solana (SOL) as its primary treasury reserve asset.
Regenerex Pharma, Inc.
Pharmaceutical Preparations
Vicarious Surgical Inc.
RBOT · Orthopedic, Prosthetic & Surgical Appliances & Supplies
Päivitetty: 24.9.2026